Dr. Matthew T. Bartock, D.O
Hematology & Oncology (Hematology & Oncology Physician)
11050 Parkview Circle Dr
Fort Wayne, IN 46845
Who else practices at this address →
Allen County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 191
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IN license 02006296A · PA license OT016741 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Parkview Regional Medical Center Fort Wayne, IN
- Parkview Whitley Hospital Columbia City, IN
- Parkview Noble Hospital Kendallville, IN
- Parkview Wabash Hospital, Inc Wabash, IN
- Adams Memorial Hospital Decatur, IN
Medical groups
- Parkview Health System Inc (1,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 191
- Services billed
- 594
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 274 | 158 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 42 | 19 |
| New patient office or other outpatient visit, 45-59 minutes | 28 | 28 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 24 | 23 |
| Established patient office or other outpatient visit, 40-54 minutes | 16 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Fort Wayne, IN | 404 |
| Acyclovir Other prescribers in Fort Wayne, IN | 129 |
| Xarelto (rivaroxaban) Other prescribers in Fort Wayne, IN | 121 |
| Hydroxyurea Other prescribers in Fort Wayne, IN | 107 |
| Folic Acid Other prescribers in Fort Wayne, IN | 58 |
| Calquence (acalabrutinib maleate) | 46 |
| Ondansetron Hcl Other prescribers in Fort Wayne, IN | 41 |
| Revlimid (lenalidomide) | 40 |
| Lenalidomide | 36 |
| Levofloxacin Other prescribers in Fort Wayne, IN | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $46.49 in total to this clinician.
| Merck Sharp & Dohme LLC | $32.91 |
|---|---|
| Genzyme Corporation | $13.58 |
| Food and Beverage | $46.49 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $64,728 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
AbbVie Inc. · Active, not recruiting · NCT05578976 - M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.